Indications for: KAPVAY
Attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications.
<6yrs: not recommended. Swallow whole. Individualize. Titrate by response. Initially 0.1mg at bedtime for 1 week, then 0.1mg twice daily for 1 week, then 0.1mg in the morning and 0.2mg at bedtime for 1 week, then 0.2mg twice daily. Withdraw gradually; reduce by 0.1mg/day at 3–7 day intervals.
Do not substitute with other clonidine products on a mg-per-mg basis. Monitor heart rate and BP prior to initiation, after dose increases, and periodically during therapy. Hypotension, bradycardia, heart block, vascular disease, cardio- or cerebrovascular disease, chronic renal failure, cardiac conduction abnormalities: titrate slowly and monitor. History of, or conditions that predispose to syncope. Dehydration. Elevated temperature. Avoid abrupt discontinuation to minimize risk of rebound hypertension. Renal impairment. Pregnancy. Nursing mothers: monitor infants.
Central alpha-2 agonist.
Potentiated by alcohol, other CNS depressants (eg, benzodiazepines, antipsychotics, barbiturates); avoid. Potentiates AV block, bradycardia with drugs that affect sinus node function or AV node conduction (eg, digitalis, calcium channel blockers, β-blockers); avoid. Additive effects with antihypertensives; monitor. Hypotensive effects may be antagonized by tricyclic antidepressants; monitor. May need to adjust dose of concurrent stimulant medication.
Somnolence, fatigue, irritability, insomnia, nightmares, constipation, dry mouth, decreased appetite, dizziness; bradycardia, allergic reactions.
Renal. Half-life: 12–16 hours.